NYSEAMERICAN:CVM Cel-Sci (CVM) Stock Price, News & Analysis $1.66 0.00 (0.00%) Closing price 09/18/2026 04:10 PM EasternExtended Trading$1.65 -0.01 (-0.60%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Cel-Sci Stock (NYSEAMERICAN:CVM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cel-Sci alerts:Sign Up Key Stats Today's Range$1.51▼$1.7050-Day Range$1.14▼$1.7252-Week Range$0.89▼$10.83Volume264,960 shsAverage Volume118,831 shsMarket Capitalization$29.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cel-Sci Corporation is a biotechnology company focused on developing investigational immunotherapies for cancer and infectious diseases. The company’s lead product candidate is Multikine (leukocyte interleukin injection), an immunotherapy designed to stimulate the immune system against cancer. Multikine has primarily been studied as a potential treatment for patients with newly diagnosed, locally advanced primary head and neck cancer before standard surgery, radiation, or chemotherapy. Cel-Sci also develops therapies using its LEAPS (Ligand Epitope Antigen Presentation System) technology platform. The platform is designed to direct and regulate immune responses and has been investigated for potential applications in infectious diseases, autoimmune disorders, and cancer. These products remain investigational and are subject to clinical and regulatory evaluation. Founded in 1983, Cel-Sci is headquartered in Vienna, Virginia. The company has conducted clinical development activities in the United States and internationally. Geert Kersten serves as the company’s chief executive officer and has been involved in leading Cel-Sci’s development programs.AI Generated. May Contain Errors. Read More Cel-Sci Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreCVM MarketRank™: Cel-Sci scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Cel-Sci. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cel-Sci is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cel-Sci is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCel-Sci has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.97% of the float of Cel-Sci has been sold short.Short Interest Ratio / Days to CoverCel-Sci has a short interest ratio ("days to cover") of 5.12.Change versus previous monthShort interest in Cel-Sci has recently increased by 9.52%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCel-Sci does not currently pay a dividend.Dividend GrowthCel-Sci does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Cel-Sci this week, compared to 0 articles on an average week.Search Interest4 people have searched for CVM on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Cel-Sci to their MarketBeat watchlist in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cel-Sci insiders have not sold or bought any company stock.Percentage Held by Insiders14.06% of the stock of Cel-Sci is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions12.08% of the stock of Cel-Sci is held by institutions.Read more about Cel-Sci's insider trading history. Receive CVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cel-Sci and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CVM Stock News HeadlinesCEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and LaryngologySeptember 15, 2026 | finance.yahoo.comCEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and LaryngologySeptember 15, 2026 | businesswire.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory ...August 4, 2026 | finance.yahoo.comCEL-SCI Corporate Event Calendar | AMEX:CVMJuly 16, 2026 | benzinga.comCEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck CancerJuly 13, 2026 | finance.yahoo.comCEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer CareJune 24, 2026 | businesswire.comCEL-SCI Announces Closing of OfferingJune 16, 2026 | businesswire.comSee More Headlines CVM Stock Analysis - Frequently Asked Questions How have CVM shares performed this year? Cel-Sci's stock was trading at $5.26 at the beginning of the year. Since then, CVM shares have decreased by 68.4% and is now trading at $1.66. How were Cel-Sci's earnings last quarter? Cel-Sci Corporation (NYSEAMERICAN:CVM) released its earnings results on Friday, August, 14th. The company reported ($0.47) earnings per share for the quarter. When did Cel-Sci's stock split? Cel-Sci's stock reverse split on the morning of Thursday, June 15th 2017.The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Cel-Sci? Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cel-Sci own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cel-Sci investors own include Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), Savara (SVRA), Gilead Sciences (GILD) and Company Calendar Last Earnings8/14/2026Today9/20/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CVM's financial health is in the Red zone, according to TradeSmith. CVM has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:CVM CIK725363 Webcel-sci.com Phone703-506-9460Fax703-506-9471Employees44Year Founded1983Profitability EPS (Trailing Twelve Months)($9.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-250.83% Return on Assets-125.06% Debt Debt-to-Equity Ratio0.35 Current Ratio1.48 Quick Ratio1.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.32 per share Price / Book0.72Miscellaneous Outstanding Shares17,480,000Free Float15,020,000Market Cap$29.02 million OptionableNo Data Beta0.61 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSEAMERICAN:CVM) was last updated on 9/21/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cel-Sci Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Cel-Sci With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
